Inpatient Glycemic Control - Basal Bolus Insulin Protocol

Key Points

• For most noncritically ill adults, target glucose is 100 to 180 mg/dL when achievable safely.
• Persistent glucose around 180 mg/dL or higher generally warrants therapy initiation or intensification.
• Basal-prandial-correction insulin is preferred for patients eating reliably.
• Basal plus correction insulin is preferred for poor or no oral intake.
• Prolonged correction-only insulin is discouraged.
• Type 1 diabetes requires basal insulin even when NPO.
• Renal dysfunction and reduced intake increase hypoglycemia risk.
• Discharge planning is part of inpatient glycemic treatment.

Algorithm

1. Identify known diabetes, stress hyperglycemia, steroid use, and current nutrition.
2. Check A1C when recent status is unknown and result will affect planning.
3. Set an individualized inpatient glucose target, usually 100 to 180 mg/dL outside the ICU.
4. Choose basal-prandial-correction for reliable intake or basal-plus-correction for poor intake.
5. Use IV insulin in critical illness or metabolic emergencies when appropriate.
6. Monitor glucose at intervals matched to meals, NPO status, feeds, and insulin regimen.
7. Treat any hypoglycemia immediately and reduce the causative insulin or nutrition mismatch.
8. Reconcile medications, education, supplies, and follow-up before discharge.

Clinical Synopsis & Reasoning

Hospital hyperglycemia can reflect known diabetes, previously unrecognized diabetes, stress physiology, glucocorticoids, enteral or parenteral nutrition, or medication effects. Obtain an A1C on admission when recent results are unavailable and the result will help distinguish chronic from stress hyperglycemia. Point-of-care glucose frequency should match nutrition and therapy, commonly before meals and bedtime in patients who are eating and every 4 to 6 hours in those who are not.

The 2026 ADA hospital standard recommends 100 to 180 mg/dL for most noncritically ill patients when this can be achieved without significant hypoglycemia. For most critically ill adults, a target around 140 to 180 mg/dL is appropriate after treatment is initiated for persistent hyperglycemia. Persistent glucose at or above about 180 mg/dL generally warrants initiation or intensification of therapy. More stringent targets may be appropriate for selected stable patients, while less aggressive targets may be safer in people with high hypoglycemia risk or limited life expectancy.

Insulin choice follows physiology and feeding status. A patient who is eating reliably needs basal insulin for fasting and between-meal hepatic glucose production, prandial insulin for carbohydrate intake, and correction insulin for unexpected hyperglycemia. A patient with poor or no oral intake generally needs basal insulin plus correction, with prandial doses held. Type 1 diabetes always requires basal insulin even when NPO to prevent ketosis. Renal dysfunction, reduced intake, older age, and abrupt steroid taper increase hypoglycemia risk and should lower dosing.

Treatment Strategy & Disposition

Use scheduled subcutaneous insulin for most noncritically ill patients. Estimate the initial total daily dose from prior home insulin, body size, glycemic pattern, kidney function, nutritional intake, and insulin sensitivity. Lower weight-based starting doses are appropriate for frail adults, advanced CKD, and high hypoglycemia risk; higher doses may be needed with obesity or high-dose glucocorticoids. Divide scheduled insulin into basal and nutritional components rather than relying on repeated reactive correction doses.

For reliable oral intake, administer rapid-acting insulin with meals plus basal insulin. For poor intake or NPO status, use basal plus correction insulin. Coordinate insulin timing with enteral feeds, parenteral nutrition, and interruptions. If continuous tube feeding stops unexpectedly after insulin has been given, hypoglycemia prevention may require dextrose and more frequent monitoring. Glucocorticoid hyperglycemia often follows the pharmacologic profile of the steroid; NPH can be useful with daytime prednisone, while longer steroid exposure may require broader basal-prandial coverage.

IV insulin is preferred in many critically ill patients, DKA/HHS, or situations requiring rapid titration. Every hospital regimen must include a hypoglycemia protocol. Recurrent glucose below 70 mg/dL should trigger treatment and reassessment of insulin dosing, nutrition, kidney function, and medication timing. Before discharge, reconcile the outpatient regimen, provide supplies and education, and arrange follow-up, especially for newly recognized diabetes or major medication changes.

Epidemiology / Risk Factors

• Hyperglycemia is common in hospitalized patients both with and without known diabetes.
• Stress hyperglycemia is associated with worse outcomes, but overly intensive insulin treatment increases hypoglycemia.
• Insulin remains the preferred inpatient glucose-lowering therapy in many acute clinical situations.
• Transitions between ICU, ward, procedures, nutrition plans, and discharge are high-risk moments for medication error.

Investigations

Special Situations

Pharmacology

Prognosis / Complications

• Reasonable glucose control reduces symptomatic hyperglycemia while avoiding harm from aggressive targets.
• Severe or recurrent hypoglycemia is associated with poor inpatient outcomes.
• Newly recognized elevated A1C predicts ongoing outpatient diabetes risk rather than transient stress alone.
• Clear discharge planning reduces medication confusion and early readmission.

Patient Education / Counseling

• Explain that hospital insulin needs may differ from home needs because illness, steroids, and nutrition change rapidly.
• Teach signs and treatment of hypoglycemia before discharge.
• Confirm access to glucose-monitoring supplies and insulin equipment.
• Explain any temporary steroid-related insulin plan and how it changes when steroids taper.
• Arrange timely outpatient follow-up for new diabetes or major regimen changes.

Notes

The older concept of a sliding scale as the default inpatient regimen has been replaced by physiologic scheduled insulin. Repeated correction doses chase hyperglycemia after it occurs and ignore basal hepatic glucose production and meal-related needs.

The 2026 ADA Standards specify a 100 to 180 mg/dL target for most noncritically ill hospitalized patients. This target should still be individualized when hypoglycemia risk, severe comorbidity, or unusual circumstances make a different range safer.

References

1. ADA Standards of Care in Diabetes 2026: Diabetes Care in the Hospital — Link
2. American Diabetes Association Standards of Care in Diabetes — Link